Oncoinvent ASA (0RU5) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Martin Ohlin and I would like to welcome you to the third quarter 2024 update from BergenVaya. I would like to remind everyone about the forward looking statement. The Q3 highlights and post-period highlights, i.e. the period after the third quarter, importantly consists of significant updates from the BGB16 study, our study of benzantamib in the frontline therapy in non-small cell lung cancer for STK11 mutated patients. the enrollment in the Phase 1b study, and we saw an encouraging safety profile, but also, importantly, we saw that the plasma levels of benzantamib were in the therapeutic relevant window, which is also encouraging, and it confers very well to what we saw in the BGB008 study, which was in the second line, non-small cell lung cancer study, We are advancing the collaboration with Tempus, such that the contextual benchmark arm will be available when we are announcing the Phase 2a results, and even with the interim data. The recruitment activities are now fully up to speed, with all sites being activated. I'll come back to that a little bit later. And we now expect the first interim analysis of the Phase 2a study to occur in the first part of 2025. I think we can say that it's really encouraging that SDK-level mutated patients in frontline therapy consists or represents a significant unmet medical need, and the publication of data that supports this continues to evolve. It is that 20% of the population in frontline therapy that actually have SDK11 mutations. So that's reassuring from a market potential. But we also believe that given the mechanism of action of benzenzimib, we might be able to show a difference by stimulating the immune response from the current standard of care, which is checkpoint inhibition combined with platin...